Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...
Check Out Our Latest Analysis on BHVN Biohaven Stock Performance Shares of NYSE:BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm ...
Equity ETFs kicked off 2025 with subdued flows as more money went into fixed income funds. According to a recently released FactSet report, inflows to U.S. equity ETFs nearly halved by the end of ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
2-Year U.S. Treasury Note Continuous Contract $102.676 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $106.250-0.016-0.01% 10-Year U.S. Treasury Note Continuous Contract $108.922-0.047 ...
Megan McCluskey is a staff writer at TIME. She covers culture, focusing on horror, fantasy, and science fiction. More From TIME ...
Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...
US stocks bounced back on Monday as investors looked beyond President Trump's latest tariff threats, including new levies on steel and aluminum imports. Investors weighed Trump's recent pledge to ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback